Merck KGaA
Merck KGaA pushes biosimilars
February 12, 2014Research and Development, Sales and Marketing Dr Reddy's, Merck KGaA, biosimilars, dr reddys, generics
Merck KGaA is to take big strides into the world of biosimilars, according to the German company’s chairman Karl-Ludwig Kley. …
Merck KGaA head jumping ship to Lanxess
January 29, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Merck, Merck KGaA, lanxess, zachert
Merck KGaA’s chief financial officer Matthias Zachert is exiting the firm in order to fulfill a chief executive appointment at …
Merck KGaA declines in Q2
August 7, 2013Sales and Marketing Erbitux, Merck KGaA, Q2, Serono
Sales of cancer drug Erbitux dropped as Merck Serono’s revenues for the second quarter of 2013 dipped year-on-year, the firm …
Merck, Hedinger first suppliers certified under excipient scheme
August 1, 2013Manufacturing and Production Merck, Merck KGaA
Merck KGaA’s EMD Millipore unit and fellow German firm Hedinger have become the first two excipient suppliers to be certified …
Merck KGaA/BMS China deal
March 22, 2013Sales and Marketing BMS, Merck KGaA, diabetes
Merck KGaA and Bristol-Myers Squibb are to co-promote the German firm’s veteran diabetes drug Glucophage in different formations in China. …
Knee trial for Merck KGaA
March 19, 2013Research and Development, Sales and Marketing Merck KGaA, knee, nordic
Merck KGaA is to begin a Phase IIb trial of its investigational drug sprifermin in patients with osteoarthritis (OA) of …
Merck KGaA pipeline hit
December 21, 2012Research and Development, Sales and Marketing Cancer, Merck KGaA, NSCLC, pipeline
Merck KGaA’s pipeline has been dented by the ‘disappointing’ late-stage failure of Stimuvax in a programme with non-small cell lung …
Merck KGaA licences new cancer candidate
September 10, 2012Research and Development, Sales and Marketing Cancer, EGFR, Merck KGaA, oncology
Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …
Merck KGaA confirms leadership team appointments
June 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMD Serono, Merck KGaA, Serono
The subsidiary of Merck KGaA named EMD Serono has announced several appointments to its leadership team. The appointments include: Allene …
Merck KGaA’s colon cancer drug fails trial
May 16, 2012Research and Development, Sales and Marketing Erbitux, Merck KGaA, Merck Serono, colon cancer
Merck KGaA has suffered a setback with key brand Erbitux as the colerectal cancer drug failed in a late-stage trial. …
Merck KGaA sets out savings target as staff threaten to strike
May 15, 2012Research and Development, Sales and Marketing Merck KGaA, R&D, Serono, cuts
Merck KGaA has outlined its plan to make €300 million in savings from its Serono drugs unit, with over half …
Merck KGaA swings axe over Serono operations
April 25, 2012Manufacturing and Production, Research and Development, Sales and Marketing Cladribine, MS, Merck KGaA, Switzerland, job cuts
Merck KGaA will cut around 500 jobs from its pharmaceutical unit in Switzerland, the firm has announced. The company said …
Merck KGaA manufacturing under scrutiny by FDA
March 27, 2012Manufacturing and Production FDA, Merck KGaA, Rebif, Violations, manufacturing
The US Food and Drug Administration has asked Merck KGaA to undertake a ‘comprehensive and global assessment’ of its manufacturing …
Mini-labs to fight counterfeit drugs in Africa
March 2, 2012Sales and Marketing Africa, Merck KGaA, Zambia, counterfeits
Merck KGaA is donating equipment which can detect counterfeit drugs, while also increasing its commitment to eradicating schistosomiasis in Africa. …
Rebif approved for early use in MS
January 26, 2012Sales and Marketing MS, Merck KGaA, Merck Serono, Rebif
The European Commission has approved an indication for multiple sclerosis treatment Rebif that treats early signs of the condition.This EC …
